Janus Henderson Group PLC Purchases Shares of 3,105,669 Jade Biosciences, Inc. $JBIO

Janus Henderson Group PLC acquired a new stake in Jade Biosciences, Inc. (NASDAQ:JBIO) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 3,105,669 shares of the company’s stock, valued at approximately $43,557,000. Janus Henderson Group PLC owned 0.06% of Jade Biosciences at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Legal & General Group Plc bought a new stake in shares of Jade Biosciences in the 2nd quarter valued at about $29,000. Russell Investments Group Ltd. acquired a new stake in Jade Biosciences in the 2nd quarter valued at about $31,000. BNP Paribas Financial Markets bought a new position in Jade Biosciences during the second quarter worth about $32,000. California State Teachers Retirement System grew its holdings in Jade Biosciences by 40.3% during the fourth quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock worth $44,000 after purchasing an additional 819 shares during the period. Finally, Group One Trading LLC grew its holdings in Jade Biosciences by 122.9% during the fourth quarter. Group One Trading LLC now owns 4,195 shares of the company’s stock worth $65,000 after purchasing an additional 22,527 shares during the period.

Jade Biosciences Stock Performance

NASDAQ:JBIO opened at $19.75 on Monday. Jade Biosciences, Inc. has a 52 week low of $6.67 and a 52 week high of $28.00. The firm has a market cap of $974.86 million, a price-to-earnings ratio of -9.78 and a beta of 1.49. The firm’s 50-day simple moving average is $19.70 and its 200 day simple moving average is $18.28.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05). Sell-side analysts anticipate that Jade Biosciences, Inc. will post -2.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on JBIO. Piper Sandler set a $55.00 price objective on Jade Biosciences in a research note on Tuesday, June 2nd. Wedbush lifted their target price on Jade Biosciences from $34.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 2nd. Zacks Research upgraded Jade Biosciences from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Jade Biosciences in a report on Monday, June 1st. Finally, UBS Group began coverage on shares of Jade Biosciences in a research report on Monday, June 15th. They set a “buy” rating and a $45.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.57.

Jade Biosciences Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.